New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;  ; ribavirin 400mg;   - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 400mg   excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90553 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg;  ; ribavirin 600mg;   - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg   excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 600mg   excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90623 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbvie limited - brimonidine tartrate 2 mg/ml;  ; timolol maleate 6.8 mg/ml equivalent to timolol base 5 mg/ml;   - eye drops, solution - 2mg/ml, 5mg/ml - active: brimonidine tartrate 2 mg/ml   timolol maleate 6.8 mg/ml equivalent to timolol base 5 mg/ml   excipient: benzalkonium chloride dibasic sodium phosphate heptahydrate hydrochloric acid monobasic sodium phosphate monohydrate purified water sodium hydroxide - combigan® eye drops are indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension not adequately responding to monotherapy.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbvie limited - brimonidine tartrate 2 mg/ml;   - eye drops, solution - 0.2 % - active: brimonidine tartrate 2 mg/ml   excipient: benzalkonium chloride citric acid monohydrate hydrochloric acid polyvinyl alcohol purified water sodium chloride sodium citrate dihydrate sodium hydroxide - alphagan® eye drops are effective for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbvie limited - brimonidine tartrate 1.5 mg/ml;   - eye drops, solution - 1.5 mg/ml - active: brimonidine tartrate 1.5 mg/ml   excipient: boric acid calcium chloride dihydrate carmellose sodium hydrochloric acid magnesium chloride hexahydrate potassium chloride purified water sodium borate pentahydrate sodium chloride sodium chlorite as purite sodium hydroxide - alphagan® p 1.5 eye drops are effective for lowering intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 50 mg/ml;  ;   - solution for injection - 20mg/0.4ml - active: adalimumab 50 mg/ml     excipient: citric acid monohydrate dibasic sodium phosphate dihydrate mannitol monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride sodium citrate sodium hydroxide water for injection - humira in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years of age and older. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 50 mg/ml;  ;   - solution for injection - 40 mg/0.8ml - active: adalimumab 50 mg/ml     excipient: citric acid monohydrate dibasic sodium phosphate dihydrate dimeticone mannitol monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 50 mg/ml;  ;   - solution for injection - 40 mg/0.8ml - active: adalimumab 50 mg/ml     excipient: citric acid monohydrate dibasic sodium phosphate dihydrate dimeticone mannitol monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride sodium citrate dihydrate sodium hydroxide water for injection - rheumatoid arthritis humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate. humira can be used alone or in combination with methotrexate.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

abbvie limited - adalimumab 50 mg/ml;  ;   - solution for injection - 10 mg/0.2 ml - active: adalimumab 50 mg/ml     excipient: citric acid monohydrate dibasic sodium phosphate dihydrate mannitol monobasic sodium phosphate dihydrate polysorbate 80 sodium chloride sodium citrate sodium hydroxide water for injection - humira in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years of age and older. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

abbvie limited - levobupivacaine hydrochloride - solution for injection/infusion - 2.5 milligram(s)/millilitre - amides; levobupivacaine